CDTX vs. RLAY, TYRA, ANAB, KURA, CRMD, ABUS, PHAR, IMTX, ORIC, and RAPP
Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), AnaptysBio (ANAB), Kura Oncology (KURA), CorMedix (CRMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Immatics (IMTX), ORIC Pharmaceuticals (ORIC), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry.
Cidara Therapeutics vs.
Relay Therapeutics (NASDAQ:RLAY) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Relay Therapeutics presently has a consensus target price of $20.50, indicating a potential upside of 422.96%. Cidara Therapeutics has a consensus target price of $32.20, indicating a potential upside of 49.98%. Given Relay Therapeutics' higher possible upside, equities research analysts clearly believe Relay Therapeutics is more favorable than Cidara Therapeutics.
In the previous week, Cidara Therapeutics had 4 more articles in the media than Relay Therapeutics. MarketBeat recorded 6 mentions for Cidara Therapeutics and 2 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.07 beat Cidara Therapeutics' score of 0.52 indicating that Relay Therapeutics is being referred to more favorably in the media.
97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are held by institutional investors. 4.3% of Relay Therapeutics shares are held by company insiders. Comparatively, 7.6% of Cidara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cidara Therapeutics received 392 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 70.36% of users gave Cidara Therapeutics an outperform vote while only 69.41% of users gave Relay Therapeutics an outperform vote.
Cidara Therapeutics has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Cidara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Relay Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
Relay Therapeutics has a net margin of 0.00% compared to Cidara Therapeutics' net margin of -289.05%. Relay Therapeutics' return on equity of -45.75% beat Cidara Therapeutics' return on equity.
Summary
Cidara Therapeutics beats Relay Therapeutics on 10 of the 19 factors compared between the two stocks.
Get Cidara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cidara Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CDTX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free CDTX Stock Alerts